97 related articles for article (PubMed ID: 16133531)
1. Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced pancreatic or biliary cancers.
Ramanathan RK; Fakih M; Mani S; Deutsch M; Perez RP; Ritter MA; Eiseman JL; Ivy SP; Trump DL; Belani CP; Parise RA; Potter DM; Egorin MJ
Cancer Chemother Pharmacol; 2006 Apr; 57(4):465-74. PubMed ID: 16133531
[TBL] [Abstract][Full Text] [Related]
2. Results of the phase I dose-escalating study of motexafin gadolinium with standard radiotherapy in patients with glioblastoma multiforme.
Ford JM; Seiferheld W; Alger JR; Wu G; Endicott TJ; Mehta M; Curran W; Phan SC
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(3):831-8. PubMed ID: 17560737
[TBL] [Abstract][Full Text] [Related]
3. Noninvasive and nondestructive optical spectroscopic measurement of motexafin gadolinium in mouse tissues: comparison to high-performance liquid chromatography.
Kanick SC; Eiseman JL; Joseph E; Guo J; Parker RS
J Photochem Photobiol B; 2007 Sep; 88(2-3):90-104. PubMed ID: 17604637
[TBL] [Abstract][Full Text] [Related]
4. Multicenter phase Ib/II trial of the radiation enhancer motexafin gadolinium in patients with brain metastases.
Carde P; Timmerman R; Mehta MP; Koprowski CD; Ford J; Tishler RB; Miles D; Miller RA; Renschler MF
J Clin Oncol; 2001 Apr; 19(7):2074-83. PubMed ID: 11283141
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of motexafin gadolinium and doxorubicin in the treatment of advanced malignancies.
Traynor AM; Thomas JP; Ramanathan RK; Mody TD; Alberti D; Wilding G; Bailey HH
Invest New Drugs; 2011 Apr; 29(2):316-22. PubMed ID: 19997959
[TBL] [Abstract][Full Text] [Related]
6. Motexafin gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: a Children's Oncology Group phase I study.
Bradley KA; Pollack IF; Reid JM; Adamson PC; Ames MM; Vezina G; Blaney S; Ivy P; Zhou T; Krailo M; Reaman G; Mehta MP;
Neuro Oncol; 2008 Oct; 10(5):752-8. PubMed ID: 18715950
[TBL] [Abstract][Full Text] [Related]
7. MRI measurement of the uptake and retention of motexafin gadolinium in glioblastoma multiforme and uninvolved normal human brain.
Wu GN; Ford JM; Alger JR
J Neurooncol; 2006 Mar; 77(1):95-103. PubMed ID: 16547607
[TBL] [Abstract][Full Text] [Related]
8. Motexafin gadolinium combined with prompt whole brain radiotherapy prolongs time to neurologic progression in non-small-cell lung cancer patients with brain metastases: results of a phase III trial.
Mehta MP; Shapiro WR; Phan SC; Gervais R; Carrie C; Chabot P; Patchell RA; Glantz MJ; Recht L; Langer C; Sur RK; Roa WH; Mahe MA; Fortin A; Nieder C; Meyers CA; Smith JA; Miller RA; Renschler MF
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1069-76. PubMed ID: 18977094
[TBL] [Abstract][Full Text] [Related]
9. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
[TBL] [Abstract][Full Text] [Related]
10. Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer.
Rao GG; Rogers P; Drake RD; Nguyen P; Coleman RL
Gynecol Oncol; 2005 Jan; 96(1):168-72. PubMed ID: 15589596
[TBL] [Abstract][Full Text] [Related]
11. Paclitaxel and concurrent radiation therapy for locally advanced adenocarcinomas of the pancreas, stomach, and gastroesophageal junction.
Safran H; Akerman P; Cioffi W; Gaissert H; Joseph P; King T; Hesketh PJ; Wanebo H
Semin Radiat Oncol; 1999 Apr; 9(2 Suppl 1):53-7. PubMed ID: 10210540
[TBL] [Abstract][Full Text] [Related]
12. A phase I single-dose trial of gadolinium texaphyrin (Gd-Tex), a tumor selective radiation sensitizer detectable by magnetic resonance imaging.
Rosenthal DI; Nurenberg P; Becerra CR; Frenkel EP; Carbone DP; Lum BL; Miller R; Engel J; Young S; Miles D; Renschler MF
Clin Cancer Res; 1999 Apr; 5(4):739-45. PubMed ID: 10213207
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses.
Tamura K; Nakagawa K; Kurata T; Satoh T; Nogami T; Takeda K; Mitsuoka S; Yoshimura N; Kudoh S; Negoro S; Fukuoka M
Cancer Chemother Pharmacol; 2007 Jul; 60(2):285-93. PubMed ID: 17136542
[TBL] [Abstract][Full Text] [Related]
14. A phase II study of oral S-1 with concurrent radiotherapy followed by chemotherapy with S-1 alone for locally advanced pancreatic cancer.
Shinchi H; Maemura K; Mataki Y; Kurahara H; Sakoda M; Ueno S; Hiraki Y; Nakajo M; Natsugoe S; Takao S
J Hepatobiliary Pancreat Sci; 2012 Mar; 19(2):152-8. PubMed ID: 21647560
[TBL] [Abstract][Full Text] [Related]
15. A phase I trial of S-1 with concurrent radiotherapy for locally advanced pancreatic cancer.
Ikeda M; Okusaka T; Ito Y; Ueno H; Morizane C; Furuse J; Ishii H; Kawashima M; Kagami Y; Ikeda H
Br J Cancer; 2007 Jun; 96(11):1650-5. PubMed ID: 17533388
[TBL] [Abstract][Full Text] [Related]
16. Phase-I trial of oral fluoropyrimidine anticancer agent (S-1) with concurrent radiotherapy in patients with unresectable pancreatic cancer.
Shinchi H; Maemura K; Noma H; Mataki Y; Aikou T; Takao S
Br J Cancer; 2007 May; 96(9):1353-7. PubMed ID: 17437021
[TBL] [Abstract][Full Text] [Related]
17. Aggressive simultaneous radiochemotherapy with cisplatin and paclitaxel in combination with accelerated hyperfractionated radiotherapy in locally advanced head and neck tumors. Results of a phase I-II trial.
Kuhnt T; Becker A; Pigorsch S; Pelz T; Bloching M; Passmann M; Lotterer E; Hänsgen G; Dunst J
Strahlenther Onkol; 2003 Oct; 179(10):673-81. PubMed ID: 14566475
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial of concurrent hyperfractionated split course radiotherapy (HFx RT), cisplatin (cDDP), and paclitaxel in patients with recurrent, previously irradiated, or treatment-naïve locally advanced upper aerodigestive malignancy.
Langer CJ; Duffy K; Horwitz EM; Litwin S; Rosvold E; Schol J; Keenan E; Nicolaou N; Friedman CD; Ridge JA
Cancer Invest; 2006 Mar; 24(2):164-73. PubMed ID: 16537186
[TBL] [Abstract][Full Text] [Related]
19. Phase I clinical trial of the novel platin complex dicycloplatin: clinical and pharmacokinetic results.
Li S; Huang H; Liao H; Zhan J; Guo Y; Zou BY; Jiang WQ; Guan ZZ; Yang XQ
Int J Clin Pharmacol Ther; 2013 Feb; 51(2):96-105. PubMed ID: 23127487
[TBL] [Abstract][Full Text] [Related]
20. A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation.
Rinaldi DA; Kuhn JG; Burris HA; Dorr FA; Rodriguez G; Eckhardt SG; Jones S; Woodworth JR; Baker S; Langley C; Mascorro D; Abrahams T; Von Hoff DD
Cancer Chemother Pharmacol; 1999; 44(5):372-80. PubMed ID: 10501910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
